Thyroid function after diagnostic 123I-metaiodobenzylguanidine in children with neuroblastic tumors

Clément, Sarah; Tytgat, Godelieve A.M.; Trotsenburg, A S Paul van; Kremer, Leontien; Santen, Hanneke M van

doi:10.1007/s12149-022-01743-7

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is important because diabetes mellitus significantly limits cardiac MIBG performance due to the higher number of false-positive results associated with this condition. However, one important drawback of directly studying thyroid tissue is the thyroid damage related to the radionuclide 123I in [123I]-MIBG [41]. Nevertheless, further studies with other organs and radionuclides in patients with PD should be performed to improve the understanding of the pathophysiologic mechanisms underlying neurodegeneration in this condition.…”

Section: Cardiac Mibg Scintigraphy Techniquementioning

confidence: 99%

Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review

Pitton Rissardo,

Fornari Caprara

2023

Brain Sciences

View full text Add to dashboard Cite

Cardiac sympathetic denervation, as documented on 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy, is relatively sensitive and specific for distinguishing Parkinson’s disease (PD) from other neurodegenerative causes of parkinsonism. The present study aims to comprehensively review the literature regarding the use of cardiac MIBG in PD. MIBG is an analog to norepinephrine. They share the same uptake, storage, and release mechanisms. An abnormal result in the cardiac MIBG uptake in individuals with parkinsonism can be an additional criterion for diagnosing PD. However, a normal result of cardiac MIBG in individuals with suspicious parkinsonian syndrome does not exclude the diagnosis of PD. The findings of cardiac MIBG studies contributed to elucidating the pathophysiology of PD. We investigated the sensitivity and specificity of cardiac MIBG scintigraphy in PD. A total of 54 studies with 3114 individuals diagnosed with PD were included. The data were described as means with a Hoehn and Yahr stage of 2.5 and early and delayed registration H/M ratios of 1.70 and 1.51, respectively. The mean cutoff for the early and delayed phases were 1.89 and 1.86. The sensitivity for the early and delayed phases was 0.81 and 0.83, respectively. The specificity for the early and delayed phases were 0.86 and 0.80, respectively.

show abstract

Section: Cardiac Mibg Scintigraphy Techniquementioning

confidence: 99%

Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review

Pitton Rissardo,

Fornari Caprara

2023

Brain Sciences

View full text Add to dashboard Cite

show abstract

Pharmacological protection of the thyroid gland against radiation damage from radioactive iodine labeled compounds in children: a systematic review

Lijster

Kanter

Keizer

et al. 2022

Clin Transl Imaging

View full text Add to dashboard Cite

Purpose There is currently no consensus on which protective strategy is most effective to prevent I-131 uptake in the thyroid during medical interventions in children. We aimed to collect the best available evidence to determine which pharmacological intervention is most effective in protecting the thyroid gland from damage by radioactive iodine (RAI). Methods Literature searches were performed using PubMed, Embase, OLDMEDLINE, and the Cochrane Central Register of Controlled Trials. Only original studies were included (1950–2022). Studies comparing pharmacological prevention of the thyroid against RAI uptake or occurrence of hypothyroidism, thyroid nodule or thyroid cancer were included. Included studies were graded according to the Grading of Recommendations Assessment, Development and Evaluation considerations. Pharmacological interventions were compared for effectiveness on reduction of thyroidal intake or relevant clinical thyroidal outcomes. Results Forty studies were included. Quality of included studies was low and many different outcome variables were used, making meta-analysis impossible. In 81% of studies, the pharmacological intervention could not prevent RAI uptake or thyroid damage. The administration of potassium iodide (KI) 1 h before exposure to RAI seemed most effective to reduce thyroidal uptake, however, hypothyroidism was reported in up to 64% as well as several cases of thyroid carcinoma. The combination of KI, thyroxine and thiamazole reduced RAI uptake and occurrence of hypothyroidism; yet, after follow-up of 9 years, still 50% of patients developed hypothyroidism. KI with potassium perchlorate showed hypothyroidism to occur in up to 12% of patients after short follow-up time. Conclusions The lack of well-designed studies impairs making strong recommendations on the optimal way to prevent thyroid damage when using radioactive coupled ligands for medical interventions. To improve the protection of the thyroid against radiation damage by I-131, well-designed randomized clinical trials with sufficient follow-up time, comparing new protective strategies’ effects on valid and well-defined thyroid outcomes are needed.

show abstract

Thyroid function after diagnostic 123I-metaiodobenzylguanidine in children with neuroblastic tumors

Cited by 2 publications

References 20 publications

Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review

Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review

Pharmacological protection of the thyroid gland against radiation damage from radioactive iodine labeled compounds in children: a systematic review

Contact Info

Product

Resources

About